

Special Issue

Advances in the Treatment of Metastatic Uveal Melanoma

Message from the Guest Editor

Uveal malignant melanoma (UM) is a disease that differs biologically from cutaneous melanoma, which is reflected by a different mutation profile and a markedly lower tumor mutation burden in UM. Current treatments of the primary tumor in UM are effective using local radiotherapy or surgery. For patients developing metastatic disease, mainly engaging the liver, the situation is more challenging, with no approved drugs as of today. Recent initiatives including exploration of both local and systemic approaches are in clinical development and are using interventions in both monotherapy and in combinations. Further efforts remain to be uncovered in the clinical setting in order to improve the therapeutic outcomes for this group of patients with a high medical need. The purpose of this issue on metastatic UM will be to offer an updated overview of the present and potentially soon new therapeutic options in metastatic UM in the clinic.

Guest Editor

Prof. Dr. Lars Ny

Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy & Sahlgrenska University Hospital, University of Gothenburg, SE413 45 Gothenburg, Sweden

Deadline for manuscript submissions

closed (31 May 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/82705

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)